Article Sidebar

PDF
Date Published: 12/04/2023
Abstract Views: 214
Views PDF: 108
DOI: https://doi.org/10.51298/vmj.v525i1A.4910
Issue
Vol. 525 No. 1A (2023)
Section
Các bài báo
How to Cite
Đỗ , H. N., Nguyễn, T. Q. ., & Nguyễn, T. T. . (2023). TREATMENT RESULTS OF R-GEMOX REGIMEN IN RELAPSED/REFRACTORY B CELL LYMPHOMA WITHOUT HIGH-DOSE CHEMOTHERAPY INDICATIONS AT THE K HOSPITAL 2019-2022. Vietnam Medical Journal, 525(1A). https://doi.org/10.51298/vmj.v525i1A.4910

TREATMENT RESULTS OF R-GEMOX REGIMEN IN RELAPSED/REFRACTORY B CELL LYMPHOMA WITHOUT HIGH-DOSE CHEMOTHERAPY INDICATIONS AT THE K HOSPITAL 2019-2022

Huyền Nga Đỗ 1,, Tiến Quang Nguyễn1, Thanh Tùng Nguyễn1
1 k hospital

Main Article Content

Abstract

Objectives: To evaluate the treatment results and some side effects of R-GEMOX regimen in relapsed/refractory B-cell non-Hodgkin's lymphoma without high-dose chemotherapy indications at the K hospital from 2019 to 2022; Subjects and methods: A prospective, cross-sectional study performed on 40 patients with relapsed/refractory B cell non-Hodgkin lymphoma treated at the Hematologic Oncology Department, K Hospital from 05/2019-11/2022. Results: Mean age was 61.7; male/female ratio=1; 90% of the patients received 1 prior chemotherapy regimen. The median time from last regimen to R-GEMOX was 10 months. Patients with stage 4 when relapsed/refractory accounted for 35%. Most of the patients with histopathology could be DLBCL, accounting for 87.5%. Overall response rate was 60%, of which the rate of complete response was 17.5%; partial response was 42.5%; Stable disease rate was 2.5%; disease progression rate was 37.5%; Toxicity grade 3 or higher accounted for 17.5%. The median progression free survival was 15 months. The median overall survival was 20 months. Conclusion: R-GEMOX regimen prolongs progression-free survival as well as overall survival and is safe for patients with relapsed/refractory B-cell non-Hodgkin lymphoma without high-dose chemotherapy indications.

Article Details

Keywords

R/R NHL (Relapsed/Refractory B-cell non-Hodgkin lymphoma)

References

1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. . N Engl J Med. 1995;333:1540–1545.
2. Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progressionfree survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918–3927.
3. Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am. 1997;11:937–947.
4. T. El Gnaoui, J. Dupuis, K. Belhadj et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Annals of Oncology. 2007:1363–1368.
5. Clarisse Cazelles, Karim Belhadj, Hélène Vellemans et al. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. Leuk Lymphoma. 2021;62(9):2161-2168.
6. Dumontet C, Morschhauser F, Solal-Celigny P et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin’s lymphoma. Br J Haematol. 2001;113:772–778.
7. Fossa A, Santoro A, Hiddemann W et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3786–3792.
8. Andrew D.Z. et al. NCCN Clinical practice guidelines in Oncology - B-Cell lymphomas. NCCN. 2020:12-65.